Finac issued a follow-up report on the vaccine industry for 2024 on 14 february. The distribution of priority vaccines for the fiscal year 2024: for the fiscal year 2024: for the fiscal year 2024: for the fiscal year 2024: for the fiscal year 2024; for the same year, there was an increase in the number of five, four, 27 (+17 per cent); and 100 (+10 per cent) for the sanofe paste. Pneumonia vaccine: in the 2024 fiscal year, 71 batches (-23 per cent) were issued for 13-priced pneumonia vaccines, of which 27 batches were issued by pfizer, 22 batches by manami and 22 batches by watson. Thirty-nine batches (-34%) of the 23-priced pneumonia vaccine were issued. Hpv vaccine: 195 batches (64%) issued in 2024 fiscal year. Of these, 89 batches of hpv vaccine were issued at double cost. Of these, 69 batches (-78 per cent), 15 batches (-44 per cent) of weston biology, and 5 batches (-50 per cent) of gsk; 2 batches (-95 per cent) of the meshadon iv vaccine; and 104 batches (-30 per cent) of the meshadong ix vaccine. Vegetable herpes vaccine: 88 batches of herpes vaccine were issued for 2024 fiscal years, 39 batches for 100 grams of organisms and 49 batches for gsk. Influenza vaccine: in fiscal year 2024, the trivalent influenza vaccine was issued in 115 batches and the trivalent influenza vaccine was issued in 166 batches; and the rotavirus vaccine: in the 2024 fiscal year, 109 batches (-29 per cent) were issued for the rota influenza vaccine: in the 2024 fiscal year, 7 batches of meningitis vaccine were issued: in the 2024 fiscal year, 414 batches (-13 per cent) of meningitis vaccine were issued for other major vaccines: in the 2024 fiscal year, 777 batches (+9 per cent) of pox vaccine were issued for human rabies: in the 2024 fiscal year, 274 batches (-8 per cent). Hib vaccine: 37 batches (-5%) issued in 2024 fiscal year. Vaccination against intestinal viruses: ev71 was issued 73 batches (-17%) for the 2024 fiscal year. Overall: in fiscal year 2024, most batches were issued down and some were warmed up. Of these, 2 batches (-95 per cent) and 104 batches (-30 per cent) were issued by the smart-flying biological agent meshadong, and 56 batches (-24 per cent) were issued by the agent meshadong pentavalent viral vaccine. A total of 69 batches (-78 per cent) of hpv vaccine were achieved at the wanthai bivalent. 27 batches (+17%) and 22 batches (+47%) of 13-priced pneumonia vaccine were issued by the minami bibli-hib iv. Forty-two batches (46%) of rabies vaccine were issued in the convergence and 21 batches (-22%) were issued in the orin biosorption vaccine. Twenty-five batches of the concino 4 priced meningitis combined vaccine. Hepatitis b vaccine from the north china pharmaceutical company was issued 101 batches (+42%). 98 batches (+1 per cent) of 100 grams of biopox vaccine were issued; 7 batches of a nasal flu vaccine and 39 batches of a herpes vaccine were issued. The relevant targets are concino, contai biology, orin biology, pecker biology, conhua biology, hualand biology, dick dick king, north china pharmaceuticals, wise flying biology, wantai biology, big life, etc。
